Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Smooth Muscle Res ; 43(5): 191-9, 2007 Oct.
Article in English | MEDLINE | ID: mdl-18075228

ABSTRACT

Diabetic gastropathy is suggested to be the result of not only an autonomic neuropathy but also to disorder of the spontaneous rhythmic motility of the gastric smooth muscle. Attempts were made to investigate the alteration of the effects of endothelin-1 (ET-1), which is known to enhance the spontaneous activity of gastrointestinal smooth muscle, on gastric activity in streptozotocin (STZ)-induced diabetic rats. STZ-induced diabetic rats were prepared by the injection of Sprague-Dawley (SD) rats with STZ (i.p.). Isometric mechanical responses were recorded in isolated circular smooth muscle strips of the stomach antrum, to measure changes in the rhythmicity of the smooth muscle. ET-1 (10 nM) significantly elevated the resting tension and the frequency of spontaneous contraction, but did not alter the amplitude of the spontaneous oscillatory contractions in normal rats. In diabetic rats, ET-1 elevated the resting tension, and spontaneous contractions were increased in frequency, however they were decreased in amplitude. In normal rats, sarafotoxin S6c (S6c, 10 nM), a selective ET(B) receptor agonist, elevated the resting tension slightly and increased both the frequency and amplitude of the spontaneous contractions. However, S6c significantly elevated the resting tension alone in STZ-induced diabetic rats. Selective stimulation of endothelin type A (ET(A)) receptors with ET-1, in the presence of a selective antagonist of ET(B) receptors, produced similar responses in the gastric muscle of both normal and diabetic rats. These results indicate that ET-1 elevates the resting tension and increases the frequency of the spontaneous oscillatory contractions in both normal and STZ-induced diabetic rats, to a similar extent. However, the specific actions on ET(B) receptors were quite different between the two: the elevating actions on the resting tension were much greater in STZ-diabetic rats than in normal rats. The results suggested the facilitation of ET(B) receptor signaling in the antrum during the pathogenesis of diabetic gastropathy.


Subject(s)
Diabetes Complications/etiology , Diabetes Mellitus, Experimental/complications , Endothelin-1/pharmacology , Muscle Contraction , Muscle, Smooth/physiopathology , Pyloric Antrum/physiopathology , Stomach Diseases/etiology , Animals , Blood Glucose/analysis , Body Weight , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Pyloric Antrum/drug effects , Rats , Rats, Sprague-Dawley , Receptor, Endothelin B/agonists , Stomach/drug effects , Stomach/physiopathology
2.
Endocr J ; 54(5): 751-5, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17878609

ABSTRACT

Ascites caused by hypothyroidism is rare and the pathogenesis is unclear. Several reports have presented cases of progressive ascites with hypothyroidism and elevated tumor markers. We report a 31-year-old female case with massive ascites and elevated serum CA 125 concentrations. The patient had no typical feature of hypothyroidism except an accumulation of ascitic fluid which showed elevated total protein concentration and a high serum-ascites albumin gradient (SAAG). There was no finding of malignancy. Following thyroid hormone replacement, the ascites was completely resolved accompanied by reduced concentrations of serum CA125. In general, primary hypothyroidism with ascites presents with coexisting massive pericardial or pleural effusion. The massive ascites and increased serum CA125 concentrations may have led us to make the incorrect diagnosis of ovarian malignancy. The evaluation of thyroid function is useful to determine the pathology of high-protein ascites or elevated tumor markers, and ascites may be treatable by thyroid replacement therapy.


Subject(s)
Ascites/complications , Ascites/diagnosis , CA-125 Antigen/analysis , Hypothyroidism/complications , Adult , Female , Hormone Replacement Therapy , Humans , Hypothyroidism/blood , Hypothyroidism/drug therapy , Immunoglobulins, Thyroid-Stimulating/analysis , Immunoglobulins, Thyroid-Stimulating/blood , Thyroxine/administration & dosage
3.
Nephrology (Carlton) ; 10(4): 400-4, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16109089

ABSTRACT

BACKGROUND: We recently showed that there were clear regional differences in the dynamics of end-stage renal disease (ESRD) within Japan, which has an ethnically homogenous population. We speculate on the reason for these regional differences by correlating the regional distributions in the incidence of ESRD due to each of the following individual causes of ESRD: chronic glomerulonephritis (CGN), diabetic nephropathy (DMN) and polycystic kidney disease (PKD). METHODS: The number of ESRD patients entering maintenance dialysis therapy due to individual causes of renal disease in each prefecture was reported annually for a 6-year period by the Japanese Society for Dialysis Therapy. After combining data from several prefectures into 11 geopolitical regions in Japan, the mean annual incidence of ESRD across the 11 regions was correlated among the three causes of ESRD. RESULTS: There were significant regional differences in the incidence of ESRD due to CGN (P<0.0001) and DMN (P=0.0015), the distributions of which were similar to each other across the 11 regions. In contrast, no regional differences were found in the incidence of ESRD due to PKD (P=0.6) as the major genetic disorder of the kidneys, suggesting that genetic backgrounds are relatively uniform throughout Japan. The regional distributions due to PKD were not correlated with those due to other causes: CGN and DMN. CONCLUSION: Risk factors common to nephropathy progression, rather than an underlying disease incidence and genetic predisposition, might contribute to regional differences in the overall ESRD incidence in Japan. Other possibilities such as the prevalence of underlying diseases, and acceptance or rejection rates into treatment programmes must be considered further for better explanations.


Subject(s)
Kidney Failure, Chronic/epidemiology , Chronic Disease , Diabetic Nephropathies/complications , Glomerulonephritis/complications , Humans , Incidence , Japan/epidemiology , Kidney Failure, Chronic/etiology , Polycystic Kidney Diseases/complications , Risk Factors
4.
Int J Gynecol Pathol ; 24(1): 79-84, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15626921

ABSTRACT

We report a case of solitary fibrous tumor of the uterus producing high-molecular-weight insulin-like growth factor II (big IGF-II). A 78-year-old woman presented with a massive uterine tumor and worsening hypoglycemia. Endocrine and metabolic investigations revealed that her serum contained big IGF-II. Pathologic examination of the myometrial tumor showed spindle cells separated by thick collagen fibers. The tumor cells were immunoreactive for CD34 and IGF-II (inclusive of big IGF-II) but not smooth muscle actin or desmin. Postoperatively the hypoglycemia and the serum big IGF-II disappeared with recovery of suppressed insulin and growth hormone levels. Western blotting of the tumor extract revealed the presence of big IGF-II, the molecular weight of which was similar to that of aberrant serum IGF-II. To our knowledge, this is the first case of uterine solitary fibrous tumor.


Subject(s)
Hypoglycemia/etiology , Insulin-Like Growth Factor II/biosynthesis , Neoplasms, Fibrous Tissue/metabolism , Uterine Neoplasms/metabolism , Aged , Blotting, Western , Female , Humans , Immunohistochemistry , In Situ Hybridization , Insulin-Like Growth Factor II/chemistry , Molecular Weight , Neoplasms, Fibrous Tissue/complications , Neoplasms, Fibrous Tissue/diagnosis , Neoplasms, Fibrous Tissue/surgery , Tomography, X-Ray Computed , Uterine Neoplasms/complications , Uterine Neoplasms/diagnosis , Uterine Neoplasms/surgery
5.
Kidney Int ; 65(2): 621-5, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14717933

ABSTRACT

BACKGROUND: We reported that patients with sodium sensitive type of hypertension exhibited the lack of nocturnal fall in blood pressure with enhanced natriuresis during night. Sodium sensitivity is caused by diminished glomerular filtration capability and/or augmented tubular reabsorption of sodium, and seems tightly linked with glomerular capillary hypertension. In the present study, we investigated the relationship between glomerular filtration rate and circadian rhythms of these parameters in patients with glomerulopathy. METHODS: Twenty six patients (15 men and 11 women; aged 17 to 72 years; mean age 47 +/- 3 years), whose diagnosis was confirmed as glomerulopathy with renal biopsy, were studied during hospitalization. Ambulatory blood pressure for 24 hours was monitored, while urinary samples were collected for both daytime (6:00 a.m. to 9:00 p.m.) and nighttime (9:00 p.m. to 6:00 a.m.) to estimate circadian rhythms of urinary sodium and protein excretion rates (UNaV, UproV). Then night/day ratios of mean arterial blood pressure (MAP), UNaV, and UproV were analyzed in relation to 24-hour creatinine clearance as a marker of glomerular filtration rate. RESULTS: Serum creatinine and creatinine clearance were 1.1 +/- 0.1 mg/dL and 89 +/- 7 mL/min/1.73 m2. There were significant day-night differences in MAP (96 +/- 2 mm Hg vs. 92 +/- 2 mm Hg; P= 0.006), UNaV (6.7 +/- 0.9 mmol/hour vs. 3.6 +/- 0.3 mmol/hour; P= 0.003), and UproV (161 +/- 27 mg/hour vs. 128 +/- 28 mg/hour; P= 0.02). Creatinine clearance had significantly negative relationships with night/day ratios of MAP (r=-0.49; P= 0.01), UNaV (r=-0.43; P= 0.03,) and UproV (r=-0.41; P= 0.04). In addition, night/day ratio of MAP had significantly positive relationships with night/day ratios of UNaV (r= 0.49; P= 0.01) and UproV (r= 0.45; P= 0.02). CONCLUSION: Our results show that as renal function deteriorates in glomerulopathy the nocturnal dip in blood pressure is lost, resulting in enhanced urinary sodium and protein excretions during night. These findings are compatible with our proposal that impaired natriuresis during daytime makes nocturnal blood pressure elevated to compensate for diminished natriuresis by pressure natriuresis. We speculate that nocturnal glomerular capillary hypertension contributes, at least in part, to enhanced urinary sodium and protein excretions during night.


Subject(s)
Blood Pressure/physiology , Circadian Rhythm/physiology , Hypertension, Renal/physiopathology , Natriuresis/physiology , Proteinuria/physiopathology , Adult , Female , Glomerular Filtration Rate , Humans , Male , Middle Aged , Sodium/urine
7.
Clin Exp Nephrol ; 7(2): 120-4, 2003 Jun.
Article in English | MEDLINE | ID: mdl-14586730

ABSTRACT

BACKGROUND: Although it has been repeatedly shown that the oral carbonaceous absorbent AST-120 ameliorates the progression of chronic renal failure, the mechanisms remain unknown. METHODS: Male Sprague-Dawley rats (6 weeks old), weighing 180-210 g, were 4/5 nephrectomized, and were divided into two groups: one given AST-120 (0.4 g/100 g body weight BW; n= 9) and the other not given AST-120 ( n = 9). Body weight, blood pressure, and serum and urine chemistry, as well as the plasma components of the renin-angiotensin system, were measured for 22 weeks. RESULTS: Proteinuria was significantly greater in the controls than in the AST-120 group (102 +/- 22 vs 51 +/- 7 mg/day at 22 weeks). Urea clearance was lower in the former (3.7 +/- 0.4 vs 3.9 +/- 0.4 ml/min). There were no differences in plasma renin activity (1.4 +/- 0.3 vs 1.9 +/- 0.4 mg/ml per h), or in angiotensin I (756 +/- 119 vs 1042 +/- 168 pg/ml) and II (35.1 +/- 7.4 vs 46.6 +/- 7.6 pg/ml) or angiotensin-converting enzyme activity (39.0 +/- 2.4 vs 37.9 +/- 2.2 IU/l) between the two groups. Protein intake, estimated from urinary urea appearance, was not different. Serum phosphate concentration (6.6 +/- 0.3 vs 5.9 +/- 0.3 mg/dl) was higher in the control than in AST-120, while the urinary phosphate excretion rate (31.5 +/- 0.8 vs 28.1 +/- 1.8 mg/day) tended to be lower in the latter. Conclusions. AST-120 retarded the progression of renal failure in the 4/5 renal ablation model without affecting the plasma renin-angiotensin system or protein intake, both of which were the most important risk factors for the progression of renal failure. We hypothesize that the renal protective effects of the oral absorbent AST-120 may be, at least in part, due to its lowering phosphate absorption from the diet as a phosphorus binder.


Subject(s)
Carbon/therapeutic use , Dietary Proteins , Kidney Failure, Chronic/drug therapy , Oxides/therapeutic use , Renin-Angiotensin System/physiology , Adsorption , Animals , Blood Chemical Analysis , Blood Pressure , Body Weight , Disease Models, Animal , Hematocrit , Humans , Kidney Failure, Chronic/blood , Male , Nephrectomy , Phosphates/blood , Phosphates/urine , Proteinuria , Rats , Rats, Sprague-Dawley
8.
Kidney Int ; 64(4): 1445-9, 2003 Oct.
Article in English | MEDLINE | ID: mdl-12969164

ABSTRACT

BACKGROUND: We recently found regional differences in the incidence of end-stage renal disease (ESRD) in Japan, which is generally ethnically homogeneous, suggesting that factors other than genetic may contribute to the difference. Here, we examined regional differences in the amounts of expenses spent on antihypertensives, especially angiotensin-converting enzyme (ACE) inhibitors, in our search for an explanation. METHODS: Annually, the Japanese Society for Dialysis Therapy reports the numbers of patients entering maintenance dialysis in each prefecture of Japan since 1982. We used the findings for 1995 to 2000 to calculate the annual incidence of ESRD in each of the 11 regions of Japan. In addition, regional differences in annual amounts paid for antihypertensive drugs, presumably corresponding to the amounts used, during the same 6 years, corrected for population, were estimated. RESULTS: As in our 1982 to 1998 study, the incidence of ESRD was high in Okinawa, Kyushu, and Shikoku, while low in Hokuriku, Koshinetsu, and Tohoku (P < 0.0001) [one-way repeated measures analysis of variance (ANOVA)]. We found regional differences in the corrected sum paid for total antihypertensive drugs, ACE inhibitors and calcium antagonists. Only ACE inhibitors were negatively correlated with the incidence of ESRD by linear and multiple regression analyses. CONCLUSION: The renal protective effects of ACE inhibitors have been established by results with animal models of progressive nephropathy and large-scale clinical trials. Our epidemiologic results for Japan as a whole show the same protective effects still more convincingly from a different approach.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Demography , Drug Prescriptions/statistics & numerical data , Kidney Failure, Chronic/drug therapy , Kidney Failure, Chronic/epidemiology , Humans , Incidence , Japan , Regression Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...